Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Nervous System Diseases | 3 | 2013 | 694 | 0.430 |
Why?
|
| Epidemiologic Measurements | 1 | 2009 | 22 | 0.350 |
Why?
|
| Candidiasis, Oral | 2 | 2017 | 58 | 0.260 |
Why?
|
| HIV-1 | 4 | 2015 | 6827 | 0.230 |
Why?
|
| Mouth Diseases | 2 | 2016 | 235 | 0.220 |
Why?
|
| HIV Infections | 8 | 2017 | 17006 | 0.200 |
Why?
|
| Anti-HIV Agents | 3 | 2013 | 4443 | 0.190 |
Why?
|
| Erythrocyte Deformability | 2 | 2015 | 55 | 0.150 |
Why?
|
| Nystatin | 1 | 2017 | 22 | 0.140 |
Why?
|
| Gentian Violet | 1 | 2017 | 30 | 0.140 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2015 | 2572 | 0.140 |
Why?
|
| Warts | 1 | 2016 | 66 | 0.130 |
Why?
|
| Diagnosis, Oral | 1 | 2015 | 23 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2009 | 5049 | 0.120 |
Why?
|
| Environmental Exposure | 1 | 2009 | 4340 | 0.120 |
Why?
|
| Erythrocytes | 2 | 2015 | 2400 | 0.120 |
Why?
|
| Plasmodium yoelii | 1 | 2014 | 42 | 0.120 |
Why?
|
| Blood Preservation | 1 | 2015 | 168 | 0.120 |
Why?
|
| Antifungal Agents | 1 | 2017 | 711 | 0.100 |
Why?
|
| Guanine | 1 | 2013 | 276 | 0.100 |
Why?
|
| Glutamates | 1 | 2013 | 391 | 0.100 |
Why?
|
| Polybrominated Biphenyls | 1 | 2009 | 25 | 0.090 |
Why?
|
| Statistical Distributions | 1 | 2009 | 63 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 636 | 0.080 |
Why?
|
| Michigan | 1 | 2009 | 339 | 0.080 |
Why?
|
| Azetidines | 1 | 2009 | 136 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2013 | 6482 | 0.080 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2015 | 812 | 0.080 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 1247 | 0.080 |
Why?
|
| Spleen | 1 | 2014 | 2274 | 0.070 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2014 | 820 | 0.070 |
Why?
|
| Odds Ratio | 3 | 2014 | 9701 | 0.070 |
Why?
|
| Prevalence | 5 | 2016 | 15506 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2013 | 3308 | 0.070 |
Why?
|
| Lymphoma, B-Cell | 1 | 2013 | 929 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2013 | 1265 | 0.070 |
Why?
|
| Likelihood Functions | 1 | 2009 | 987 | 0.070 |
Why?
|
| Anti-Retroviral Agents | 1 | 2016 | 1771 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2013 | 3088 | 0.070 |
Why?
|
| Water Pollutants, Chemical | 1 | 2009 | 343 | 0.070 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2006 | 141 | 0.060 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 905 | 0.060 |
Why?
|
| Nervous System Malformations | 1 | 2006 | 245 | 0.060 |
Why?
|
| Malaria | 1 | 2014 | 1207 | 0.060 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 1594 | 0.060 |
Why?
|
| Plasmodium falciparum | 1 | 2013 | 1731 | 0.050 |
Why?
|
| Hypercholesterolemia | 1 | 2009 | 1154 | 0.050 |
Why?
|
| Anticholesteremic Agents | 1 | 2009 | 985 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2009 | 2277 | 0.050 |
Why?
|
| Health Personnel | 1 | 2015 | 3266 | 0.050 |
Why?
|
| Infant Mortality | 1 | 2006 | 747 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2005 | 935 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 2407 | 0.040 |
Why?
|
| Sex Factors | 1 | 2013 | 10455 | 0.040 |
Why?
|
| Disease Progression | 2 | 2013 | 13402 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2015 | 4714 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 3107 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2011 | 14325 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2009 | 6170 | 0.030 |
Why?
|
| Dental Hygienists | 1 | 2015 | 32 | 0.030 |
Why?
|
| Oral Medicine | 1 | 2015 | 32 | 0.030 |
Why?
|
| Middle Aged | 9 | 2017 | 217019 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 9207 | 0.030 |
Why?
|
| Adult | 9 | 2017 | 216913 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2017 | 694 | 0.030 |
Why?
|
| Female | 11 | 2017 | 386053 | 0.030 |
Why?
|
| Risk Factors | 4 | 2014 | 73412 | 0.030 |
Why?
|
| Health Behavior | 1 | 2005 | 2615 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2015 | 664 | 0.030 |
Why?
|
| Dentists | 1 | 2015 | 173 | 0.030 |
Why?
|
| Pharynx | 1 | 2016 | 429 | 0.030 |
Why?
|
| Haiti | 1 | 2015 | 545 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 1572 | 0.030 |
Why?
|
| Calibration | 1 | 2015 | 806 | 0.030 |
Why?
|
| Hemolysis | 1 | 2015 | 423 | 0.030 |
Why?
|
| Chloroquine | 1 | 2014 | 279 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2009 | 12796 | 0.030 |
Why?
|
| Male | 10 | 2017 | 354881 | 0.030 |
Why?
|
| Young Adult | 5 | 2017 | 57629 | 0.020 |
Why?
|
| Africa South of the Sahara | 1 | 2014 | 728 | 0.020 |
Why?
|
| Humans | 14 | 2017 | 752341 | 0.020 |
Why?
|
| Adolescent | 6 | 2017 | 86765 | 0.020 |
Why?
|
| Specialization | 1 | 2015 | 768 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 2016 | 1102 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2016 | 2176 | 0.020 |
Why?
|
| Microcirculation | 1 | 2014 | 1269 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 568 | 0.020 |
Why?
|
| Algorithms | 1 | 2009 | 13900 | 0.020 |
Why?
|
| Cell Separation | 1 | 2015 | 1719 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2017 | 4001 | 0.020 |
Why?
|
| Otolaryngology | 1 | 2015 | 676 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2014 | 1510 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 3463 | 0.020 |
Why?
|
| Antimalarials | 1 | 2014 | 903 | 0.020 |
Why?
|
| Viral Load | 1 | 2015 | 3297 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 6112 | 0.020 |
Why?
|
| Anemia | 1 | 2014 | 1495 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 29439 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2009 | 2032 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2015 | 25535 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2017 | 3209 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2011 | 2827 | 0.010 |
Why?
|
| Aged | 4 | 2017 | 166562 | 0.010 |
Why?
|
| California | 1 | 2005 | 1396 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 4880 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2009 | 1898 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 14586 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 58300 | 0.010 |
Why?
|
| Logistic Models | 1 | 2014 | 13277 | 0.010 |
Why?
|
| Survival Rate | 1 | 2013 | 12746 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 11064 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 15130 | 0.010 |
Why?
|
| Incidence | 1 | 2016 | 21158 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2012 | 6331 | 0.010 |
Why?
|
| Data Collection | 1 | 2005 | 3302 | 0.010 |
Why?
|
| Cause of Death | 1 | 2006 | 3686 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2009 | 12326 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 17958 | 0.010 |
Why?
|
| Child | 2 | 2012 | 78998 | 0.010 |
Why?
|
| United States | 2 | 2015 | 71442 | 0.010 |
Why?
|
| Time Factors | 1 | 2015 | 39854 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2014 | 23783 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 29327 | 0.010 |
Why?
|
| Decision Making | 1 | 2005 | 3890 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2016 | 53807 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 39079 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2013 | 79127 | 0.010 |
Why?
|
| Animals | 2 | 2014 | 166802 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2017 | 64245 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 5281 | 0.010 |
Why?
|
| Mice | 1 | 2014 | 80543 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 2006 | 25914 | 0.000 |
Why?
|
Concepts
(132)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(6)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_